Enzymatica AB (publ) (ENZY.ST) Osake Kurssi

Enzymatica AB (publ) primarily operates in the pharmaceutical and healthcare industries.

The main competitors of Enzymatica AB (publ) in the market include pharmaceutical companies such as GlaxoSmithKline, Reckitt Benckiser, and Johnson & Johnson. These companies, like Enzymatica AB (publ), are involved in the development and commercialization of healthcare products, including nasal sprays and oral care solutions. They operate in the same industry and compete for market share with Enzymatica AB (publ) by offering similar products and solutions to consumers worldwide.

Enzymatica AB (publ) is a renowned Swedish biotech company specializing in developing and marketing medical devices. Established in 2007, Enzymatica has achieved significant milestones throughout its history. The company's primary focus is on creating innovative solutions for infectious respiratory diseases, such as colds and flu. Enzymatica is widely recognized for its flagship product ColdZyme®, a mouth spray designed to reduce the risk of catching a cold. With a strong commitment to research and development, Enzymatica continues to expand its product portfolio and presence in global markets. The company's dedication to providing effective and safe healthcare products has earned it a reputable position in the industry.

Some significant milestones achieved by Enzymatica AB (publ) include the launch of their flagship product, ColdZyme®, a cold spray that targets the cause of the common cold. The company has successfully expanded its geographical reach, securing partnerships and distribution agreements in several countries. Enzymatica has also received regulatory approvals and certifications, such as CE marking, allowing them to market their products across Europe. Additionally, the company has conducted successful clinical trials, highlighting the efficacy and safety of their products. Enzymatica AB (publ) continues to innovate and collaborate in the field of healthcare, aiming to improve the lives of individuals through their effective products.

Enzymatica AB (publ) is primarily present in several countries and regions globally. The company has a strong presence in Sweden, its home country, where it is headquartered. Additionally, Enzymatica operates in other European countries including Norway, Denmark, Finland, and the United Kingdom. The company has expanded its business and distribution networks to reach markets in the Middle East, Asia, and Africa as well. With a focus on improving people's health, Enzymatica continues to explore potential opportunities for growth and expansion into new regions worldwide.

Enzymatica AB (publ) is a company that embodies strong values and a clear corporate philosophy. The company focuses on developing and offering medical devices and healthcare products based on natural substances and enzymes. Enzymatica AB (publ) values innovation, research, and sustainability, striving to enhance human health with safe, effective, and environmentally friendly solutions. The company's commitment to excellence and quality is reflected in their products, which are designed to provide effective and gentle relief for various health conditions. Enzymatica AB (publ) is dedicated to improving the overall well-being of individuals and promoting a healthier future through their natural and scientifically-validated approach.

Nykyisellä valuuttakurssilla Enzymatica AB (publ)-osake noteerataan hintaan 0,20 EUR (2,20 SEK).

Enzymatica AB (publ)-osake (ENZY.ST) on listattuna 4 pörssissä, muun muassa: Frankfurt (EN9.F), München (EN9.MU), Stockholm (ENZY.ST).

Enzymatica AB (publ) is a Swedish company specializing in the development, production, and marketing of medical products for the treatment of respiratory infections and other diseases. The company's business model is based on a combination of high-quality products, innovative technologies, and strong marketing strategies. It has three divisions: Enzymatica medical, Enzymatica consumer, and Enzymatica research. Each division is specialized in a specific market and offers a range of products tailored to the needs of its respective target audience. Enzymatica medical develops medical products for the treatment of respiratory infections, sore throats, and other diseases. Enzymatica consumer manufactures products for health promotion and disease prevention. Enzymatica research focuses on the development of new products and technologies. The company has a strong marketing strategy, utilizing social media platforms, print and online advertising, and participation in relevant conferences and trade shows. Overall, Enzymatica AB (publ) offers innovative products and technologies for the treatment and prevention of respiratory and other diseases and continues to expand its presence in pharmacies and stores.

odotettu liikevaihto Enzymatica AB (publ) on 109,00 M SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Enzymatica AB (publ) on −72,82 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Enzymatica AB (publ):n hinta-voitto-suhde (P/E) on tällä hetkellä −7,33. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Enzymatica AB (publ)-osakkeen arvostusta.

Enzymatica AB (publ):n hinta-myynti-suhde (P/S) on tällä hetkellä 4,90. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Enzymatica AB (publ)-osakkeen arvostuskennuslukuna.

Enzymatica AB (publ):n Eulpool-laatuscore on 3/10.

Enzymatica AB (publ):n ISIN on SE0003943620. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Enzymatica AB (publ):n WKN on A1WZEV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Enzymatica AB (publ):n ticker on ENZY.ST. Tämä pörssinoteeraus käytetään Enzymatica AB (publ)-osakkeiden kauppaan pörssissä.